Acura Pharmaceuticals, Inc. (ACUR) |
|
0.1 0 (0%)
|
08-08 00:16 |
|
Open: |
0.1 |
Pre. Close: |
0.1 |
|
High:
|
0.1 |
Low:
|
0.1 |
|
Volume:
|
3,691 |
Market Cap:
|
7(M) |
|
|
|
|
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.1 - 0.1 |
0.1 - 0.1 |
|
Low:
|
0.1 - 0.1 |
0.1 - 0.1 |
|
Close:
|
0.1 - 0.1 |
0.1 - 0.1 |
|
Technical analysis |
as of: 2022-08-05 4:19:56 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.36  One year: 0.58 |
| Support: |
Support1: 0 Support2: 0 |
| Resistance: |
Resistance1: 0.3 Resistance2: 0.5 |
| Pivot: |
0.19 |
| Moving Average: |
MA(5): 0.09 MA(20): 0.27
MA(100): 0.43 MA(250): 0.48 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 19.8 %D(3): 17.8 |
| RSI: |
RSI(14): 31.1 |
| 52-week: |
High: 0.63 Low: 0 |
| Average Vol(K): |
3-Month: 5 (K) 10-Days: 5 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACUR ] has closed above bottom band by 33.2%. Bollinger Bands are 179.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 05 Aug 2022
Acura Pharmaceuticals : Statement of Changes in Beneficial Ownership - Form 4 - Marketscreener.com
Sun, 10 Apr 2022
The top 3 skills needed to do a PhD are skills employers want too - The Conversation Indonesia
Mon, 16 Aug 2021
Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results - GlobeNewswire
Sat, 05 Jun 2021
How to lose weight: Sydney mum Dilay Acur shares how she shed 44kg after ditching Redbull - 7NEWS.com.au
Fri, 08 Jan 2021
Smile Robotics Makes an Autonomous Table Bussing Robot - The Spoon
Wed, 15 Nov 2017
ACUR Stock Forecast, Price & News (Acura Pharmaceuticals) - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: OTC |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
65 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
18.6 (%) |
|
% Held by Institutions
|
3 (%) |
|
Shares Short
|
90 (K) |
|
Shares Short P.Month
|
76 (K) |
Stock Financials |
|
EPS
|
-0.03 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.47 |
|
EPS Est Next Year
|
0.37 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
-51.3 |
|
Operating Margin (%)
|
-49.4 |
|
Return on Assets (ttm)
|
-38.5 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
-34.1 |
|
Gross Profit (p.s.)
|
0.02 |
|
Sales Per Share
|
0.03 |
|
EBITDA (p.s.)
|
-0.02 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-3.45 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
2.89 |
|
Price to Cash Flow
|
-16.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
